FDA-cleared profile

VIDAvision

VIDA Diagnostics Inc. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: Provides CT image analysis supporting physician diagnosis, treatment planning, and documentation of pulmonary and thoracic tissue.

Clinical role
CT image-analysis software that automatically segments lung regions with deep learning and combines 3D segmentation, volumetric and density evaluations, editing and reporting tools to support the physician in diagnosis, treatment planning and documentation of chest diseases.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Keep in mind: No human clinical testing was required in the reviewed packet.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Provides CT image analysis supporting physician diagnosis, treatment planning, and documentation of pulmonary and thoracic tissue.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/Lung Input: Thoracic CT datasets and pulmonary CT slice data retrieved through DICOM query and retrieve.
  • Who uses it?Intended users: Physicians.
  • What does the software produce?Output: Three-dimensional reconstruction, lung and subcompartment segmentation, airway and density analysis, and PDF or CSV reports.
  • What is its most important limitation?Key limitation: No human clinical testing was required in the reviewed packet.

Clinical takeaway. Clinical role: Provides CT image analysis supporting physician diagnosis, treatment planning, and documentation of pulmonary and thoracic tissue.

Evidence takeaway. Evidence from the reviewed source record: Nonclinical software, segmentation, verification, and validation testing against the predicate; no human clinical testing was required.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Provides CT image analysis supporting physician diagnosis, treatment planning, and documentation of pulmonary and thoracic tissue.
  • Exact FDA submission
  • Checked 2026-09-15

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
CT image-analysis software that automatically segments lung regions with deep learning and combines 3D segmentation, volumetric and density evaluations, editing and reporting tools to support the physician in diagnosis, treatment planning and documentation of chest diseases.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Evaluation (3D segmentation & isolation of sub-compartments, volumetric analysis, density evaluations, and low density cluster analysis), editing, and reporting tools are combined with a dedicated workflow." … "The focus of this submission is to introduce deep learning-based segmentation algorithms to the proposed software to automatically segment lung regions.". Read from the exact FDA decision document on 2026-11-14.

Required input
Thoracic CT datasets and pulmonary CT slice data retrieved through DICOM query and retrieve.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet input scope.

Output and clinician action
Three-dimensional reconstruction, lung and subcompartment segmentation, airway and density analysis, and PDF or CSV reports.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet output scope.

Care setting
Physician use on CT thoracic datasets for chest diseases, including lung cancer, asthma, COPD, interstitial lung disease and other lung abnormalities; the FDA document does not specify a facility type.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "VIDA|vision can be used to support the physician in the diagnosis, treatment planning, and documentation of chest diseases, including lung cancer, asthma, COPD, interstitial lung disease and other lung abnormalities" … "VIDA|vision can be used to support the physician in the diagnosis and documentation of pulmonary tissue images (e.g., abnormalities) from CT thoracic datasets.". Read from the exact FDA decision document on 2026-11-14.

Intended users
Physicians.
  • Exact FDA submission
  • Checked 2026-09-15

FDA packet intended-user statement.

Limitations
No human clinical testing was required in the reviewed packet.
  • Exact FDA submission
  • Checked 2026-09-15

Exact packet evidence boundary.

Evidence summary
Nonclinical software, segmentation, verification, and validation testing against the predicate; no human clinical testing was required.
  • Exact FDA submission
  • Checked 2026-09-15

Packet testing description, not clinical-performance evidence.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Nonclinical software, segmentation, verification, and validation testing against the predicate; no human clinical testing was required.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

Packet testing description, not clinical-performance evidence.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K200990. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Thoracic CT datasets and pulmonary CT slice data retrieved through DICOM query and retrieve.

    Scope: Exact FDA submission. FDA packet input scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-15 · FDA K200990: VIDAvision

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · VIDA|vision model card (K200990)

  3. AI processing

    Source context, not route validation: The exact FDA package describes VIDA|vision deployment as a standalone computer or a distributed configuration, which the predicate did not offer, on a Windows operating system. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Deployment Standalone computer/ Standalone computer Subject device distributed offers distributed configuration in addition to standalone, unlike the predicate device" … "OS Windows Linux transitioned from Linux to Windows.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K200990: VIDAvision

  4. Returned objects

    Source context, not route validation: Three-dimensional reconstruction, lung and subcompartment segmentation, airway and density analysis, and PDF or CSV reports.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-15 · FDA K200990: VIDAvision

  5. Viewer/worklist/report

    Unresolved route: Three-dimensional reconstruction, lung and subcompartment segmentation, airway and density analysis, and PDF or CSV reports.

    Scope: Exact FDA submission. FDA packet output scope.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-15 · FDA K200990: VIDAvision

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes VIDA|vision deployment as a standalone computer or a distributed configuration, which the predicate did not offer, on a Windows operating system. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Deployment Standalone computer/ Standalone computer Subject device distributed offers distributed configuration in addition to standalone, unlike the predicate device" … "OS Windows Linux transitioned from Linux to Windows.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Security
VIDA Diagnostics, Inc.'s HIPAA compliance statement describes its Business Associate obligations: a named Information Security Officer, HIPAA-compliant business associate agreements with covered entities and subcontractors, de-identification of PHI via a HIPAA-compliant protocol, breach notification commitments, and cooperation with HHS audits.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement naming VIDA Diagnostics, Inc.; vidalung.ai/legal/hipaa renders the same VIDA Intelligence content as vidaintelligence.ai/legal/hipaa. Exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for VIDAvision; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K200990
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA CT scope normalized to controlled CT bucket.

Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-15

FDA pulmonary and thoracic tissue scope.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2020-08-07
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
23Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K200990 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K200990: VIDAvision

    U.S. Food and Drug Administration - Published 2020-08-07 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. VIDA|vision model card (K200990)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, integration, anatomy, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K200990

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. VIDA Diagnostics: HIPAA Compliance Statement

    VIDA Diagnostics - Accessed 2026-10-27

    Scope: security

Research history

  1. K200990 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K251474

Median LCS (internal name) / eyonis LCS (trade name) (1.0)

Median Technologies

eyonis LCS is a concurrent-reading aid for radiologists that detects, localizes, and characterizes 4-30 mm solid and part-solid pulmonary nodules on low-dose chest CT images for high-risk lung cancer screening patients; it provides nodule measurements and malignancy scores and does not replace physician judgment.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2026-02-06
FDA-cleared K251203

AVIEW Lung Nodule CAD

Coreline Soft Co.,Ltd

Authorized purpose: Adjunctive alert and second-reader information for radiologists interpreting non-contrast chest CT in asymptomatic populations; the cleared nodule range is 3-20 mm.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2025-12-03
FDA-cleared K250766

LungQ 4

Thirona BV

Authorized purpose: Quantitative support for thoracic CT interpretation and treatment planning, including emphysema burden, airway/lung segmentation, endobronchial valve assessment and estimated chronic perfusion defect.

Modality
CT/CTA
Anatomy
Chest/Lung
Decision
2025-10-02

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history